SAN

77.86

-2.03%↓

SHL.DE

40.78

+1.39%↑

ACB

3.55

+5.65%↑

SAN

77.86

-2.03%↓

SHL.DE

40.78

+1.39%↑

ACB

3.55

+5.65%↑

SAN

77.86

-2.03%↓

SHL.DE

40.78

+1.39%↑

ACB

3.55

+5.65%↑

SAN

77.86

-2.03%↓

SHL.DE

40.78

+1.39%↑

ACB

3.55

+5.65%↑

SAN

77.86

-2.03%↓

SHL.DE

40.78

+1.39%↑

ACB

3.55

+5.65%↑

Search

Laboratorios Farmaceuticos Rovi SA

Fermé

SecteurSoins de santé

76.95 -0.45

Résumé

Variation du prix de l'action

24h

Actuel

Min

76.65

Max

77.95

Chiffres clés

By Trading Economics

Revenu

49M

76M

Ventes

51M

210M

P/E

Moyenne du Secteur

31.525

121.746

BPA

1.135

Rendement du dividende

1.26

Marge bénéficiaire

35.965

Employés

2,197

EBITDA

49M

84M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+19.68% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

1.26%

2.26%

Prochains Résultats

25 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

570M

3.8B

Ouverture précédente

77.4

Clôture précédente

76.95

Sentiment de l'Actualité

By Acuity

50%

50%

160 / 352 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 févr. 2026, 16:32 UTC

Résultats

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

13 févr. 2026, 21:57 UTC

Résultats

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13 févr. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13 févr. 2026, 21:20 UTC

Résultats

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13 févr. 2026, 21:05 UTC

Acquisitions, Fusions, Rachats

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13 févr. 2026, 20:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 févr. 2026, 20:45 UTC

Market Talk

Dollar Pares Down Early Losses -- Market Talk

13 févr. 2026, 20:39 UTC

Market Talk

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13 févr. 2026, 20:28 UTC

Market Talk

Oil Settles Week Lower -- Market Talk

13 févr. 2026, 19:51 UTC

Résultats

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 févr. 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 févr. 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 févr. 2026, 19:29 UTC

Résultats

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13 févr. 2026, 18:18 UTC

Acquisitions, Fusions, Rachats

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13 févr. 2026, 17:52 UTC

Résultats

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13 févr. 2026, 17:16 UTC

Résultats

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 févr. 2026, 17:10 UTC

Acquisitions, Fusions, Rachats

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13 févr. 2026, 16:59 UTC

Résultats

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13 févr. 2026, 16:39 UTC

Acquisitions, Fusions, Rachats

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13 févr. 2026, 16:11 UTC

Résultats

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13 févr. 2026, 16:07 UTC

Market Talk

Hungarian Forint Could Rise Further -- Market Talk

13 févr. 2026, 15:54 UTC

Résultats

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13 févr. 2026, 15:26 UTC

Market Talk

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13 févr. 2026, 15:01 UTC

Résultats

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13 févr. 2026, 15:00 UTC

Résultats

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13 févr. 2026, 14:50 UTC

Market Talk

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13 févr. 2026, 14:44 UTC

Résultats

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13 févr. 2026, 14:22 UTC

Market Talk
Résultats

Global Energy Roundup: Market Talk

13 févr. 2026, 14:21 UTC

Market Talk
Résultats

TC Energy's Broadly Anticipated Results Expected To Have Neutral Response -- Market Talk

13 févr. 2026, 14:13 UTC

Market Talk

U.S. Natural Gas Futures Move Lower -- Market Talk

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

19.68% hausse

Prévisions sur 12 Mois

Moyen 90 EUR  19.68%

Haut 90 EUR

Bas 90 EUR

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

1

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

51.1 / N/ASupport & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

160 / 352Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat